News Headlines

  1. LVV Turbo: uBriGene's New GMP Lentiviral Vector Platform With UltraCell Integration 12/16/2025

    uBriGene Biosciences, a leading global lentivirus CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced the official rebranding of its GMP lentiviral vector manufacturing platform to LVV Turbo, a high-performance system designed to deliver exceptional productivity, superior downstream yields, and a markedly lower cost of LVV manufacturing, enabling faster and more efficient vector development.

  2. Alcami Expands Drug Product Manufacturing Capacity To Meet Growing Demand 12/16/2025

    Alcami Corporation, a leading U.S. based contract development and manufacturing organization (CDMO), is proud to announce the GMP readiness of a third sterile fill-finish line at its Research Triangle Park, NC campus.

  3. RoslinCT And Ayrmid Ltd. Announce Expansion Of Strategic Partnership To Manufacture Omisirge (Omidubicel-onlv) For Second FDA-Approved Indication In Severe Aplastic Anemia (SAA) 12/16/2025

    Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge (omidubicel-onlv).

  4. PharmAla Biotech Australia Contracts With UK-based CDMO For Manufacture Of ALA-002 Drug Substance 12/15/2025

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that its wholly-owned subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO to execute manufacture of its ALA-002 drug substance.

  5. Viva Biotech's Invested And Incubated Company, Arthrosi, Has Entered Into An Acquisition Agreement With Sobi For A Total Transaction Value Of Up To US$1.5B. 12/15/2025

    Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings.

  6. Lupin Manufacturing Solutions And PolyPeptide Announce Strategic Alliance To Scale Global Peptide Supply Chain 12/12/2025

    Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited (Lupin), today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide), a specialized, global CDMO for peptide-based active pharmaceutical ingredients.

  7. Charles River Extends Commitment To Advanced Therapy Developers With Second Incubator Program Cohort 12/11/2025

    Charles River Laboratories International, Inc. today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need.

  8. Tivic Acquires Ready-To-Scale cGMP Manufacturing And Development Assets To Accelerate Commercialization Of Entolimod; Tivic Growth Backed By $90M+ Financing Package 12/11/2025

    Tivic Health Systems, Inc., a diversified therapeutics company, today announced it has acquired the strategic manufacturing and development assets of Scorpius Holdings, Inc. and is launching Velocity Bioworks, a wholly owned subsidiary of Tivic, to provide contract development and manufacturing services to Tivic and other companies.

  9. Lindus Health And Quotient Sciences Partner To Accelerate Drug Development From First-In-Human To Pivotal Trials 12/11/2025

    Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, and Quotient Sciences, a leading global clinical development and manufacturing accelerator, have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-of-concept (POC) trials.

  10. Lonza's Cocoon Platform Receives Advanced Manufacturing Technologies (AMT) Designation From The U.S. FDA 12/11/2025

    Lonza today announced that the Cocoon Platform has been granted AMT Designation by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research.